"Aurora Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of highly conserved serine-threonine kinases that are involved in the regulation of MITOSIS. They are involved in many aspects of cell division, including centrosome duplication, SPINDLE APPARATUS formation, chromosome alignment, attachment to the spindle, checkpoint activation, and CYTOKINESIS.
| Descriptor ID |
D064127
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.103 D12.776.167.049
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aurora Kinases".
Below are MeSH descriptors whose meaning is more specific than "Aurora Kinases".
This graph shows the total number of publications written about "Aurora Kinases" by people in this website by year, and whether "Aurora Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 7 | 7 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 9 | 9 |
| 2008 | 0 | 17 | 17 |
| 2009 | 0 | 12 | 12 |
| 2010 | 0 | 8 | 8 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 17 | 17 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2017 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aurora Kinases" by people in Profiles.
-
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases. Leuk Lymphoma. 2024 Nov; 65(11):1659-1674.
-
Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers. Clin Cancer Res. 2022 10 14; 28(20):4479-4493.
-
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017 Jul; 92(7):660-667.
-
Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies. Nat Commun. 2017 04 21; 8:15045.
-
Cardiac myosin binding protein C regulates postnatal myocyte cytokinesis. Proc Natl Acad Sci U S A. 2015 Jul 21; 112(29):9046-51.
-
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015 Aug; 33(4):870-80.
-
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15; 119(14):2611-9.
-
RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer. 2013 Jul 15; 133(2):275-85.
-
HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle. 2012 Nov 15; 11(22):4181-90.
-
FBXW7 is involved in Aurora B degradation. Cell Cycle. 2012 Nov 01; 11(21):4059-68.